Despite escalating criticism of exo...

Despite escalating criticism of exorbitant prices for just discovered drugs and biotech therapies, coupl with demands for access to cheap imports, policymakers continue to support the disclosure of new biomedical returnss especially those that combat life-threatening diseases and terrorist threats. The ne to maintain incentives for biotech innovation, while addressing in the same state [i]or[/i] condition hot-button issues such as follow-on generics and Medicare reimbursement, will challenge Rep James Greenwood (R-Pa) as he becomes the head of BIO (see "Greenwood to Lead BIO").
Greenwood To Lead BIO